Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. Centers for Disease Control and Prevention; 2020. p. 8.

Google Scholar 

Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25 Pt B):2985–3023. https://doi.org/10.1016/j.jacc.2013.11.004.

Article  PubMed  Google Scholar 

Curioni CC, Lourenço PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond). 2005;29(10):1168–74. https://doi.org/10.1038/sj.ijo.0803015.

Article  CAS  PubMed  Google Scholar 

Prescription medications to treat overweight & obesity. https://www.niddk.nih.gov/health-information/weight-management/prescription-medications-treat-overweight-obesity. Revised June 2021. Accessed 7 Aug 2022.

Webb PM. Obesity and gynecologic cancer etiology and survival. Am Soc Clin Oncol Educ Book. 2013. https://doi.org/10.1200/EdBook_AM.2013.33.e222.

Article  PubMed  Google Scholar 

Dag ZO, Dilbaz B. Impact of obesity on infertility in women. J Turk Ger Gynecol Assoc. 2015;16(2):111–7. https://doi.org/10.5152/jtgga.2015.15232.

Article  PubMed  PubMed Central  Google Scholar 

Chen C, Xu X, Yan Y. Estimated global overweight and obesity burden in pregnant women based on panel data model. PLoS One. 2018;13(8):e0202183. https://doi.org/10.1371/journal.pone.0202183.

Article  CAS  PubMed  PubMed Central  Google Scholar 

American College of Obstetricians and Gynecologists’ Committee on Practice, Bulletins-Obstetrics. Obesity in Pregnancy: ACOG Practice Bulletin, Number 230. Obstet Gynecol. 2021;137(6):128–44. https://doi.org/10.1097/AOG.0000000000004395.

Article  Google Scholar 

Ogunwole SM, Zera CA, Stanford FC. Obesity management in women of reproductive age. JAMA. 2021;325(5):433–4. https://doi.org/10.1001/jama.2020.21096.

Article  PubMed  PubMed Central  Google Scholar 

FDA approves new drug treatment for chronic weight management, first since 2014. FDA. Washington, DC: Center for Drug Evaluation and Research. June 2021.

Google Scholar 

Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2021.

Alabduljabbar K, Vincent RP, le Roux CW. Semaglutide is precipitating a revolution in obesity care. In: Translational Metabolic Syndrome Research. Elsevier; 2022.

Google Scholar 

WEGOVY (semaglutide injection) for subcutaneous use. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf. Revised June 2021. Accessed 8 Aug 2022.

Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138–50.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Marso SP, Holst AG, Vilsboll T. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2017;376(9):891–2. https://doi.org/10.1056/NEJMc1615712.

Article  PubMed  Google Scholar 

Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22. https://doi.org/10.1056/NEJMoa1411892.

Article  CAS  PubMed  Google Scholar 

SAXENDA (liraglutide injection) for subcutaneous use. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206321s007lbl.pdf. Revised October 2018. Accessed 8 Aug 2022.

Salamun V, Jensterle M, Janez A, Bokal EV. Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study. Eur J Endocrinol. 2018;179(1):1–11.

Article  CAS  PubMed  Google Scholar 

Nylander M, Frøssing S, Clausen HV, Kistorp C, Faber J, Skouby SO. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod Biomed Online. 2017;35(1):121–7.

Article  CAS  PubMed  Google Scholar 

Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacother J Hum Pharmacol Drug Ther. 2000;20(3):270–9.

Article  CAS  Google Scholar 

Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Clin Diabetol. 2004;5(2):95–104.

Google Scholar 

XENICAL (orlistat) capsule. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020766s029lbl.pdf. Revised January 2012. Accessed 7 Aug 2022.

Saunders KH, Umashanker D, Igel LI, Kumar RB, Aronne LJ. Obesity pharmacotherapy. Med Clin. 2018;102(1):135–48.

Google Scholar 

Pilitsi E, Farr OM, Polyzos SA, Perakakis N, Nolen-Doerr E, Papathanasiou A-E, et al. Pharmacotherapy of obesity: available medications and drugs under investigation. Metabolism. 2019;92:170–92.

Article  CAS  PubMed  Google Scholar 

Wierzbicki AS, Reynolds TM, Crook MA. Usefulness of Orlistat in the treatment of severe hypertriglyceridemia. Am J Cardiol. 2002;89(2):229–31. https://doi.org/10.1016/s0002-9149(01)02208-1.

Article  CAS  PubMed  Google Scholar 

Qsymia (phentermine and topiramate extended-release) capsules. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022580s021lbl.pdf. Revised June 2022. Accessed 9 Aug 2022.

Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kramer CK, Leitão CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obes Rev. 2011;12(5):e338–47. https://doi.org/10.1111/j.1467-789x.2010.00846.x.

Article  CAS  PubMed  Google Scholar 

Topamax (topiramate) tablets for oral use. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020505s062,020844s053lbl.pdf. Revised January 2022. Accessed 9 June 2022.

CONTRAVE (naltrexone HCl and bupropion HCl) extended release tablet. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022580s021lbl.pdf. Revised September 2014. Accessed 9 Aug 2022.

Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–409.

Article  PubMed  Google Scholar 

Gadde KM, Parker CB, Maner LG, Wagner HR, Logue EJ, Drezner MK, et al. Bupropion for weight loss: an investigation of efficacy and tolerability in overweight and obese women. Obes Res. 2001;9(9):544–51.

Article  CAS  PubMed  Google Scholar 

Fulton S, Décarie-Spain L, Fioramonti X, Guiard B, Nakajima S. The menace of obesity to depression and anxiety prevalence. Trends Endocrinol Metab. 2022;33(1):18–35.

Article  CAS  PubMed  Google Scholar 

Wellbutrin (bupropion hydrochloride) tablets. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/018644s054lbl.pdf. Accessed 9 June 2022.

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–16.

Article  CAS  PubMed  Google Scholar 

MOUNJARO (tirzepatide) injection for subcutaneous use. Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf. Revised May 2022. Accessed 9 Aug 2022.

Giruzzi N. Plenity (Oral Superabsorbent Hydrogel). Clin Diabetes. 2020;38(3):313–4. https://doi.org/10.2337/cd20-0032.

Article  PubMed  PubMed Central  Google Scholar 

Greenway FL, Aronne LJ, Raben A, Astrup A, Apovian CM, Hill JO, et al. A randomized, double-blind, placebo-controlled study of Gelesis100: a novel nonsystemic oral hydrogel for weight loss. Obesity (Silver Spring). 2019;27(2):205–16. https://doi.org/10.1002/oby.22347.

Article  CAS  PubMed  Google Scholar 

Stăcescu Ș, Hancu G, Podar D, Todea Ș, Tero-Vescan A. A historical overview upon the use of amphetamine derivatives in the treatment of obesity. J Pharm Care. 2019;7:72–9.

Google Scholar 

Kang JG, Park CY. Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J. 2012;36(1):13–25. https://doi.org/10.4093/dmj.2012.36.1.13.

Article  PubMed  PubMed Central  Google Scholar 

Lists of scheduling actions, controlled substances, regulated chemicals. In: U.S. Department of Justice DEA, Diversion Control Division, Drug & Chemical Evaluation Section, U.S. Department of Justice; Revised January 2023. Accessed January 18, 2023.

• Choi EJ, Han JY. Pregnancy outcomes after inadvertent exposure of anti-obesity drugs during pregnancy. Clin Exp Obstet Gynecol. 2021;48(3):514–22. This study is unique in that it followed pregnancy outcomes for a large group of human women (~30,000) who were inadvertently exposed to AOMs such as phentermine during pregnancy. The vast majority of studies related to human pregnancy and anti-obesity pharmacotherapy contain a very small number of subjects due to ethics concerns. This study provided a unique opportunity to observe natural data on this topic in a manner that mitigated some related ethics concerns.

Fendique ER (phendimetrazine tartrate) extended release capsules. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/018074Orig1s037lbl.pdf. Revised November 2020. Accessed 9 June 2022.

Adipex-P (phentermine) capsules. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/085128s065lbl.pdf. Revised April 2012. Accessed 9 June 2022.

Tenuate (diethylpropion hydrochloride USP) tablets. https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/11722s029,12546s032lbl.pdf. Revised November 2003. Accessed 9 June 2022.

Didrex (benzphetamine hydrochloride) tablets. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/012427s031lbl.pdf. Revised April 2020. Accessed 9 June 2022.

Glucophage (metformin hydrochloride) tablets. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020357s037s039,021202s021s023lbl.pdf. Revised April 2017. Accessed 9 June 2022.

Lentferink YE, Knibbe CAJ, Van Der Vorst MMJ. Efficacy of metformin treatment with respect to weight reduction in children and adults with obesity: a systematic review. Drugs. 2018;78(18):1887–901. https://doi.org/10.1007/s40265-018-1025-0.

Article  CAS  PubMed  Google Scholar 

Dukhovny S, Van Bennekom CM, Gagnon DR, Hernandez Diaz S, Parker SE, Anderka M, et al. Metformin in the first trimester and risks for specific birth defects in the National Birth Defects Prevention Study. Birth Defects Research. 2018;110(7):579–86. https://doi.org/10.1002/bdr2.1199.

Article  CAS  PubMed  Google Scholar 

Metformin. Drugs and Lactation Database (LactMed(R)). https://www.ncbi.nlm.nih.gov/books/NBK501020/. Revised March 2022. Accessed 18 Jan 2023.

Nommsen-Rivers L, Thompson A, Riddle S, Ward L, Wagner E, King E. Feasibility and acceptability of metformin to augment low milk supply: a pilot randomized controlled trial. J Hum Lact. 2019;35(2):261–71. https://doi.org/10.1177/0890334418819465.

Article  PubMed  PubMed Central  Google Scholar 

Vanky E, Nordskar JJ, Leithe H, Hjorth-Hansen AK, Martinussen M, Carlsen SM. Breast size increment during pregnancy and breastfeeding in mothers with polycystic ovary syndrome: a follow-up study of a randomised controlled trial on metformin versus placebo. BJOG. 2012;119(11):1403–9. https://doi.org/10.1111/j.1471-0528.2012.03449.x.

Article